LLY · News · 20260806N

Litigation - GLP-1 Antitrust Dismissal

ELI LILLY & Co · 2026-08-06 · Importance 36 · Surprise 42

A U.S. federal judge dismissed an antitrust lawsuit filed by compounding pharmacy Strive Specialties against Eli Lilly and Novo Nordisk. Strive alleged that exclusive telehealth-provider arrangements unlawfully restricted access to customized versions of GLP-1 drugs. The court found that Strive had not plausibly defined a relevant product market or adequately demonstrated competitive harm.

Key facts

• The U.S. federal judge dismissed an antitrust lawsuit by Strive Specialties against Eli Lilly and Novo Nordisk, ruling Strive failed to plausibly allege a product market or show harm. source